Hannah Faisal Almubarak, Wuwei Tan, Andrew D Hoffmann, Juncheng Wei, Lamiaa El-Shennawy, Joshua R Squires, Yuanfei Sun, Nurmaa K Dashzeveg, Brooke Simonton, Yuzhi Jia, Radhika Iyer, Yanan Xu, Vlad Nicolaescu, Derek Elli, Glenn C Randall, Matthew J Schipma, Suchitra Swaminathan, Michael G Ison, Huiping Liu, Deyu Fang, Yang Shen
Therapeutic antibodies have become one of the most influential therapeutics in modern medicine to fight against infectious pathogens, cancer, and many other diseases. However, experimental screening for highly efficacious targeting antibodies is labor-intensive and of high cost, which is exacerbated by evolving antigen targets under selective pressure such as fast-mutating viral variants. As a proof-of-concept, we developed a machine learning-assisted antibody generation pipeline that greatly accelerates the screening and re-design of immunoglobulins G (IgGs) against a broad spectrum of SARS-CoV-2 coronavirus variant strains...
March 4, 2024: bioRxiv